Treatment of liver metastases from colorectal cancer: What is the best approach today?

G. Biasco, E. Gallerani

Research output: Contribution to journalArticlepeer-review


Liver is the common site for metastases from colorectal cancer. The 5-year overall survival rate of patients following radical operations is 25%. Surgery can be carried out in only 10-15% of the patients, yet it remains the potential curative treatment for resectable lesions. For the unresectable cancers, only chemotherapy is recommended. New drugs such as Irinotecan prolongs the overall survival of patients affected by advanced disease. In patients with unresectable metastases at diagnosis, pre-surgical treatment with Oxaliplatin leads to reduction of the lesions, allowing resection in 16% of cases. Chemotherapy may be delivered directly into the liver via the hepatic artery. No, clinical trials, to date, have shown convincing survival results in patients treated with this procedure. Combined hepatic artery and systemic treatment may provide a new strategy as adjuvant therapy for patients undergoing resections.

Original languageEnglish
Pages (from-to)438-444
Number of pages7
JournalDigestive and Liver Disease
Issue number5
Publication statusPublished - 2001


  • Colorectal cancer
  • Liver metastases
  • Local chemotherapy
  • Systemic chemotherapy

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Treatment of liver metastases from colorectal cancer: What is the best approach today?'. Together they form a unique fingerprint.

Cite this